crizotinib

Drug Overview

Crizotinib is an FDA-approved oral targeted therapy that changed the standard of care for patients with certain types of non-small cell lung cancer (NSCLC) and specific pediatric cancers. It was among the first precision oncology drugs to demonstrate that identifying a specific genetic mutation in a tumor and targeting it directly could produce dramatically better outcomes than traditional chemotherapy, helping establish the foundation for modern personalized cancer medicine.

The drug works by blocking abnormal proteins produced by specific genetic alterations — most notably rearrangements in the ALK, ROS1, and MET genes — that act as primary drivers of tumor growth. When these mutated proteins are switched off by crizotinib, cancer cells lose a critical survival signal and die. This targeted approach delivers strong antitumor activity with a side effect profile generally more tolerable than conventional chemotherapy.

Key Details:

• Generic Name: Crizotinib
• US Brand Names: Xalkori
• Drug Class: Tyrosine Kinase Inhibitor (TKI) / ALK/ROS1/MET Inhibitor / Targeted Therapy
• Route of Administration: Oral (capsule)
• FDA Approval Status: FDA-approved for ALK-positive NSCLC, ROS1-positive NSCLC, and ALK-positive anaplastic large cell lymphoma and other ALK-positive solid tumors in pediatric and young adult patients.

What Is It and How Does It Work? (Mechanism of Action)

Crizotinib’s mechanism is built on a fundamental principle of precision oncology: find the specific molecular switch driving a cancer and turn it off.

Highlighted Feature: Crizotinib is a Targeted Therapy and Smart Anticancer Agent that selectively inhibits multiple mutated kinases driving tumor growth, making it one of the foundational precision medicine drugs in modern oncology.

ALK Inhibition: In approximately 3–5% of NSCLC patients, a chromosomal rearrangement fuses the ALK (anaplastic lymphoma kinase) gene with another gene, most commonly EML4, creating an abnormal fusion protein. This EML4-ALK protein is constitutively active, meaning it continuously signals cancer cells to grow and survive without any external trigger. Crizotinib binds to the ATP-binding pocket of the ALK kinase domain, blocking ATP from accessing the site. Without ATP, the kinase cannot phosphorylate its downstream targets, shutting off the growth signal entirely.

ROS1 Inhibition: ROS1 rearrangements occur in approximately 1–2% of NSCLC patients and produce a structurally similar constitutively active fusion kinase. The ROS1 kinase domain shares significant structural homology with ALK, allowing crizotinib to bind and inhibit ROS1 with comparable potency, making it effective across both molecular subtypes.

MET Inhibition: Crizotinib also inhibits the MET receptor tyrosine kinase, which is overactivated through amplification or mutation in various cancer types. MET signals through PI3K/AKT and RAS/MAPK pathways to promote tumor cell survival, proliferation, and invasion. Blocking MET suppresses these downstream cascades.

Downstream Pathway Suppression: By inhibiting ALK, ROS1, or MET, crizotinib blocks activation of STAT3, PI3K/AKT, and RAS/ERK signaling pathways simultaneously. These pathways collectively govern cell cycle progression, anti-apoptotic gene expression, and metabolic adaptation. Their combined suppression leads to cell cycle arrest and programmed cancer cell death through apoptosis.

FDA Approved Clinical Indications

Oncological Uses (FDA-Approved):

• ALK-Positive Metastatic NSCLC: First-line and previously treated adult patients with ALK gene rearrangement-positive non-small cell lung cancer
• ROS1-Positive Metastatic NSCLC: Adult patients whose tumors are ROS1 rearrangement-positive
• ALK-Positive Anaplastic Large Cell Lymphoma (ALCL): Pediatric patients aged 1 year and older and young adults with relapsed or refractory systemic ALK-positive ALCL
• ALK-Positive Inflammatory Myofibroblastic Tumor (IMT): Pediatric patients aged 1 year and older and young adults with unresectable, recurrent, or refractory ALK-positive IMT
• ALK-Positive Non-Small Cell Lung Cancer (Pediatric): Pediatric patients aged 1 year and older with ALK-positive, unresectable, recurrent, or refractory NSCLC

Non-Oncological Uses:

• None established. Crizotinib development is focused entirely on oncological applications.

Dosage and Administration Protocols

Clinical Efficacy and Research Results

PROFILE 1014 Trial (ALK-Positive NSCLC, First Line): This landmark Phase III trial compared crizotinib to platinum-based chemotherapy as first-line treatment in ALK-positive NSCLC. Crizotinib produced a progression-free survival (PFS) of 10.9 months versus 7.0 months with chemotherapy, with an objective response rate (ORR) of 74% compared to 45% for chemotherapy. These results established crizotinib as the standard of care for this molecular subtype.

ROS1-Positive NSCLC Data: In patients with ROS1-rearranged NSCLC, crizotinib demonstrated an ORR of approximately 72% with a median duration of response exceeding 17 months in pivotal studies, establishing it as the reference treatment for this molecularly defined patient group.

Pediatric ALCL and IMT (2020–2025): Updated analyses from pediatric trials confirmed durable responses in children and young adults with ALK-positive ALCL and IMT, with complete response rates reported in a meaningful proportion of heavily pretreated patients, supporting crizotinib’s approval in these rare pediatric indications.

Post-Crizotinib Landscape: While next-generation ALK inhibitors including alectinib and lorlatinib now challenge crizotinib as preferred first-line options due to superior CNS penetration and longer PFS, crizotinib remains an important and widely accessible option, particularly in resource-limited settings and for specific patient populations.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for crizotinib. However, serious adverse events including severe hepatotoxicity, interstitial lung disease, QTc prolongation, and bradycardia require careful monitoring.

Common Side Effects (>10%):

• Visual Disturbances: Flashes of light, blurry vision, and visual floaters are among the most frequently reported and distinctive side effects, occurring in the majority of patients
• Nausea and Vomiting: Very commonly reported, particularly during the first weeks of treatment
• Diarrhea and Constipation: Gastrointestinal effects affect a large proportion of patients
• Edema: Peripheral swelling and facial edema reported commonly
• Elevated Liver Enzymes: AST and ALT elevations occur frequently and require regular monitoring
• Fatigue: Generalized tiredness is commonly reported across trial populations
• Decreased Appetite: Notable reduction in appetite affecting nutritional status in some patients

Serious Adverse Events (Rare but Clinically Significant):

• Severe Hepatotoxicity: Drug-induced liver injury including fatal cases has been reported; liver function monitoring is mandatory
• Interstitial Lung Disease / Pneumonitis: Potentially fatal inflammatory lung reaction requiring immediate drug discontinuation
• QTc Prolongation: Cardiac interval prolongation requires baseline and periodic ECG monitoring
• Bradycardia: Significant heart rate slowing observed; avoid concurrent use of other bradycardia-inducing agents
• Severe Visual Loss: Rare cases of permanent vision loss reported

Management Strategies:

• Monitor liver function tests every 2 weeks during the first 2 months, then monthly thereafter
• Obtain baseline ECG and electrolyte panel; correct hypokalemia and hypomagnesemia before starting treatment
• Patients experiencing visual symptoms should undergo ophthalmological evaluation; avoid night driving if visual disturbances are present
• For Grade 3–4 hepatotoxicity or pneumonitis, withhold crizotinib immediately and do not resume until resolution; permanently discontinue for life-threatening events
• Anti-nausea medications administered prophylactically significantly reduce gastrointestinal side effect burden

Research Areas

Resistance Mechanisms and Next-Generation Sequencing: A major ongoing research area involves characterizing the molecular mechanisms by which tumors develop resistance to crizotinib, most commonly through secondary ALK kinase domain mutations or ALK gene amplification. Understanding these mechanisms has directly informed the development of next-generation ALK inhibitors and is guiding research into combination strategies that may prevent or delay resistance emergence.

Combination with Immunotherapy: Emerging research is exploring crizotinib in combination with PD-1/PD-L1 checkpoint inhibitors. ALK-positive NSCLC tumors generally have low tumor mutational burden and are considered less immunogenic than other NSCLC subtypes, suggesting that combination strategies using crizotinib’s targeted activity alongside immune activation may improve outcomes for patients who do not respond optimally to either approach alone.

Pediatric and Rare Tumor Expansion: Active research continues to expand crizotinib’s applications in pediatric oncology, including investigation in additional ALK-positive rare tumor types where the genetic driver is present but formal approval has not yet been established.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• ALK or ROS1 Molecular Testing: FDA-approved companion diagnostic testing to confirm ALK or ROS1 gene rearrangement is mandatory before initiating crizotinib
• Baseline Liver Function Tests: ALT, AST, and bilirubin required before starting and monitored throughout treatment
• Baseline ECG: QTc interval measurement and electrolyte correction before first dose
• Complete Blood Count: Baseline hematological assessment
• Ophthalmological Evaluation: Consider baseline eye examination given high frequency of visual side effects
• Pregnancy Test: Required for women of childbearing potential

Precautions During Treatment:

• Avoid concurrent use of strong CYP3A4 inhibitors (ketoconazole, clarithromycin) and inducers (rifampin, carbamazepine) as these significantly alter crizotinib plasma levels
• Avoid grapefruit and grapefruit juice throughout treatment
• Do not drive or operate heavy machinery if experiencing visual disturbances
• Women must use effective contraception during treatment and for 45 days after the final dose; men should use contraception for 90 days after the final dose

Do’s and Don’ts:

DO:

• Take crizotinib at the same times each day to maintain consistent drug levels
• Report any new or worsening shortness of breath immediately as this may indicate pneumonitis
• Attend all scheduled blood tests, ECGs, and clinical follow-up appointments
• Inform all treating physicians and pharmacists about crizotinib use before starting any new medication

DON’T:

• Do not open, crush, or chew crizotinib capsules; swallow whole
• Do not take with grapefruit juice or grapefruit products
• Do not drive at night if experiencing light flashes or visual disturbances
• Do not become pregnant during treatment without discussing contraceptive requirements with your oncologist

Legal Disclaimer

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. While crizotinib (Xalkori) is FDA-approved for specific ALK-positive and ROS1-positive cancers, treatment eligibility requires confirmed molecular testing and individual clinical evaluation by a licensed oncologist. Dosing, monitoring, and treatment decisions must be made exclusively by qualified healthcare professionals. Consult your treating oncologist before making any changes to your current treatment plan.